stockportfolio.pro
Stocks / ADMA vs OCUL
ADMA vs OCUL
ADMA Biologics, Inc. and Ocular Therapeutix, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ADMA Biologics, Inc. (ADMA) | Ocular Therapeutix, Inc. (OCUL) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $510.17M | $51.95M |
| Net income (latest FY) | $146.93M | $-265.94M |
| Revenue growth (5y CAGR) | 64.6% | 24.4% |
| Net margin | 28.8% | -511.9% |
| Return on equity | 30.8% | -40.6% |
| P/E ratio | 12.4 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ADMA — free Open OCUL — freeFrequently asked questions
Which is bigger, ADMA or OCUL?
ADMA Biologics, Inc. is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, ADMA or OCUL?
Over the last five fiscal years, ADMA Biologics, Inc. grew revenue faster — 64.6%/yr versus 24.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.